logo
Plan to scrap two-child benefit cap ‘dead in the water' after welfare U-turn

Plan to scrap two-child benefit cap ‘dead in the water' after welfare U-turn

Yahoo12 hours ago
Sir Keir Starmer will not scrap the two-child benefit cap after his U-turn on welfare cuts left a £5bn hole in Labour's spending plans.
Senior Labour figures have reportedly warned that tax hikes are on the horizon after the benefits climbdown, with a change in the controversial cap, introduced when George Osborne was chancellor, now thought to be off the table.
'My assessment is that is now dead in the water,' a No 10 source told The Sunday Times.
A source close to the chancellor added: 'MPs will need to acknowledge that there is a financial cost to not approving the welfare changes, whether that's tax rises or not scrapping the two-child benefit cap. They need to understand the trade-offs.'
The prospect of Labour keeping the two-child benefit cap in place will provoke fresh unrest among Labour backbenchers, who have a taste for rebellion after forcing Sir Keir's hand on cuts to the personal independence payment (Pip), the main disability benefit.
Sir Keir is believed to have told his cabinet he wants to scrap the two-child cap - first imposed by Osborne in 2015.
Critics of the policy, which restricts parents from claiming certain benefits for more than two of their children, say it pushes children into poverty. Charities frequently cite the £3.4bn move as one of the most cost effective ways of alleviating child poverty.
Asked on Thursday whether he still wanted to scrap the two-child cap, Sir Keir said: 'The last Labour government drove down child poverty and it's one of the proudest things that we did.
'Sadly, the last government allowed child poverty to go back up again.
'I'm determined that this government will drive it down, just as the last Labour government did.
'We've got a strategy and a task force working on this and will lay out the details of that. I personally don't think there's a silver bullet that if you do this one thing, it will deal with child poverty.' Labour's Child Poverty Taskforce, headed by work and pensions secretary Liz Kendall and education secretary Bridget Phillipson, was due to report in the spring but was delayed until the autumn.
Pressure on the PM over the two-child benefit cap will likely increase in the run up to this autumn's Budget, in which Rachel Reeves has been warned she must raise taxes or put Labour's agenda at risk.
Jim O'Neill, a former Goldman Sachs chief turned Treasury minister who quit the Conservatives and later advised Ms Reeves, said she faces no choice but to abandon key parts of her economic policy – including her commitment not to raise income tax, national insurance contributions for employees or VAT.
'Without changing some of the big taxes, welfare and pensions, they [Labour] can't commit to things like Northern Powerhouse Rail, small modular nuclear reactors, and various other things that will make an investment and growth difference,' he told The Independent.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Yahoo

timean hour ago

  • Yahoo

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on

Chart of the Week: Wall Street Has Claimed Bitcoin—Now What?
Chart of the Week: Wall Street Has Claimed Bitcoin—Now What?

Yahoo

timean hour ago

  • Yahoo

Chart of the Week: Wall Street Has Claimed Bitcoin—Now What?

"Wall Street is coming for bitcoin." That phrase used to spark both hope and fear across crypto circles. Today, it's no longer a future threat or a bullish promise—it's just reality. The original premise of bitcoin (or crypto in general)—an asset that is censorship-resistant and doesn't answer to any traditional financial institution or government—is fading fast as Wall Street giants (as well as powerful political figures) continue to establish their strong foothold in the digital assets space. During the early years of the digital assets revolution, bitcoin was celebrated as uncorrelated and unapologetically anti-establishment. TradFi asset classes like S&P 500 would rise and fall—bitcoin didn't care. What bitcoin did care about were the flaws in the traditional financial system, which are still here to this day. A major example in BTC's history that's not-so-talked about anymore is the 2013 Cyprus banking crisis. The crisis, which occurred due to overexposure of banks to overleveraged local property companies and amid Europe's debt crisis, saw deposits above 100,000 euros get a substantial haircut. In fact, 47.5% of uninsured deposits were seized. Bitcoin's response was to move sharply upward to, for the first time in its history, cross the $1,000 threshold. After a prolonged bear market over the collapse of Mt. Gox, the idea of mass adoption grew, with Wall Street's entry into the sector seen as a stamp of validation for bitcoin as it meant more liquidity, mass adoption and price maturity. That changed everything. The price might have matured, as evidenced by waning volatility. But let's face it—bitcoin is now just another macro-driven risk asset. "Bitcoin, once celebrated for its low correlation to mainstream financial assets, has increasingly exhibited sensitivity to the same variables that drive equity markets over short time frames," said NYDIC Research in a report. In fact, the correlation is now hovering near the higher end of the historical range, according to NYDIG's calculations. "Bitcoin's correlation with U.S. equities remained elevated through the end of the quarter, closing at 0.48, a level near the higher end of its historical range." Simply put, when there is blood on the street (Wall Street that is), bitcoin bleeds too. When Wall Street sneezes, bitcoin catches a cold. Even bitcoin's 'digital gold' moniker is under pressure. NYDIG notes that bitcoin's correlation to physical gold and the U.S. dollar is near zero. So much for the 'hedge' argument—at least for now. So why the shift? The answer is simple: to Wall Street, bitcoin is just another risk asset, not digital gold, which is synonymous with "safe haven." Investors are repricing everything from central bank policy whiplash to geopolitical tension—digital assets included. "This persistent correlation strength with U.S. equities can largely be attributed to a series of macroeconomic and geopolitical developments, the tariff turmoil and the rising number of global conflicts, which significantly influenced investor sentiment and asset repricing across markets," said NYDIG. And like it or not, this is here to stay—at least for a short to medium-term. As long as central bank policy, macro, and war-linked red headlines hit the tape, bitcoin will likely move in tandem with equities. "The current correlation regime may persist as long as global risk sentiment, central bank policy, and geopolitical flashpoints remain dominant market narratives," NYDIG's report said. For the maxis and long-term holders, the original vision hasn't changed. Bitcoin's limited supply, borderless access, and decentralized nature remain untouched. Just don't expect them to impact price action just yet. For now, the market sees bitcoin as just another stock ticker. Just balance your trade strategies accordingly. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Fall of a Party at Prayer
The Fall of a Party at Prayer

Wall Street Journal

timean hour ago

  • Wall Street Journal

The Fall of a Party at Prayer

Given the demographic decline of the Church of England beyond any realistic point of recovery, its constitutional presence in corridors of the establishment is more like 'Barchester Towers' than the Council of Nicaea ('Church of England, Disestablish Thyself,' Houses of Worship, June 27). In 1990 King Baudouin of the Belgians briefly abdicated rather than sign an abortion bill. One can't imagine King Charles as supreme governor doing anything like that. Belgium and Spain have Catholic monarchs without an established church. Even Russia is officially secular while Vladimir Putin and his patriarch seem problematically hand in glove. Given the remarkable independent growth of Catholicism, especially among Generation Z, ecclesiastical establishment by law is more hindrance than help, with the Church of England like a desiccated appendix in the maturing body of believers.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store